Receptor Status Differences in Prognosis for Breast Cancer
Objective: Breast cancer is a type of cancer that originates in breast tissue cells. It is the most common cancer type in the world after lung cancer. The prognosis of the disease mostly depends on the type and stage of cancer. One of the worst prognoses is seen in a specific type called Triple-nega...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Galenos Publishing House
2024-07-01
|
| Series: | Gazi Medical Journal |
| Subjects: | |
| Online Access: | https://gazimedj.com/articles/receptor-status-differences-in-prognosis-for-breast-cancer/doi/gmj.2024.2972 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850277609833758720 |
|---|---|
| author | Yelda Deligöz Bildacı Deniz Yamaç Uğur Coşkun |
| author_facet | Yelda Deligöz Bildacı Deniz Yamaç Uğur Coşkun |
| author_sort | Yelda Deligöz Bildacı |
| collection | DOAJ |
| description | Objective: Breast cancer is a type of cancer that originates in breast tissue cells. It is the most common cancer type in the world after lung cancer. The prognosis of the disease mostly depends on the type and stage of cancer. One of the worst prognoses is seen in a specific type called Triple-negative breast cancer (TNBC), which represents not having any of the three most recognized receptors, namely estrogen, progesterone, and c-erb2 receptors. Our objective was to determine the difference in overall and disease-free survival for breast cancer types categorized by receptor status.
Methods: This is a retrospective matched case-control study with breast cancer patients of two types. A total of 102 patients were divided equally into having TNBC of 51 patients in one arm and triple-positive breast cancer (TPBC) of 51 patients in the other arm. Analyses were run for disease prognostic values and patients’ demographic values.
Results: Disease free survival were 63±10.6 months and 93.2±4.9 months in the fifth year for the TNBC and TPBC groups, respectively. (p=0.004) Overall survival was significantly different as 73.9±7.3 months for TNBC and 97.7±2.3 months for TPBC (p=0.002).
Conclusion: TNBC prognosis is worse than that of other breast cancer types. The most important reason is being unable to use hormonal treatment because of the receptor status, and a disease-specific targeted treatment could not have been developed so far. Therefore, it is necessary to identify new molecular targets and develop treatments for them. |
| format | Article |
| id | doaj-art-6ac36c5ba0f24465b970247caac11658 |
| institution | OA Journals |
| issn | 2147-2092 |
| language | English |
| publishDate | 2024-07-01 |
| publisher | Galenos Publishing House |
| record_format | Article |
| series | Gazi Medical Journal |
| spelling | doaj-art-6ac36c5ba0f24465b970247caac116582025-08-20T01:49:48ZengGalenos Publishing HouseGazi Medical Journal2147-20922024-07-0135322422710.12996/gmj.2024.2972Receptor Status Differences in Prognosis for Breast CancerYelda Deligöz Bildacı0Deniz Yamaç1https://orcid.org/0000-0002-9385-3875Uğur Coşkun2Department of Internal Diseases Dokuz Eylül University Faculty of Medicine, İzmir, TürkiyeGüven Hospital Ankara, TürkiyeDepartment of Internal Diseases Gazi University Faculty of Medicine, Ankara, TürkiyeObjective: Breast cancer is a type of cancer that originates in breast tissue cells. It is the most common cancer type in the world after lung cancer. The prognosis of the disease mostly depends on the type and stage of cancer. One of the worst prognoses is seen in a specific type called Triple-negative breast cancer (TNBC), which represents not having any of the three most recognized receptors, namely estrogen, progesterone, and c-erb2 receptors. Our objective was to determine the difference in overall and disease-free survival for breast cancer types categorized by receptor status. Methods: This is a retrospective matched case-control study with breast cancer patients of two types. A total of 102 patients were divided equally into having TNBC of 51 patients in one arm and triple-positive breast cancer (TPBC) of 51 patients in the other arm. Analyses were run for disease prognostic values and patients’ demographic values. Results: Disease free survival were 63±10.6 months and 93.2±4.9 months in the fifth year for the TNBC and TPBC groups, respectively. (p=0.004) Overall survival was significantly different as 73.9±7.3 months for TNBC and 97.7±2.3 months for TPBC (p=0.002). Conclusion: TNBC prognosis is worse than that of other breast cancer types. The most important reason is being unable to use hormonal treatment because of the receptor status, and a disease-specific targeted treatment could not have been developed so far. Therefore, it is necessary to identify new molecular targets and develop treatments for them.https://gazimedj.com/articles/receptor-status-differences-in-prognosis-for-breast-cancer/doi/gmj.2024.2972breast cancerestrogen receptorprogesterone receptorher2 |
| spellingShingle | Yelda Deligöz Bildacı Deniz Yamaç Uğur Coşkun Receptor Status Differences in Prognosis for Breast Cancer Gazi Medical Journal breast cancer estrogen receptor progesterone receptor her2 |
| title | Receptor Status Differences in Prognosis for Breast Cancer |
| title_full | Receptor Status Differences in Prognosis for Breast Cancer |
| title_fullStr | Receptor Status Differences in Prognosis for Breast Cancer |
| title_full_unstemmed | Receptor Status Differences in Prognosis for Breast Cancer |
| title_short | Receptor Status Differences in Prognosis for Breast Cancer |
| title_sort | receptor status differences in prognosis for breast cancer |
| topic | breast cancer estrogen receptor progesterone receptor her2 |
| url | https://gazimedj.com/articles/receptor-status-differences-in-prognosis-for-breast-cancer/doi/gmj.2024.2972 |
| work_keys_str_mv | AT yeldadeligozbildacı receptorstatusdifferencesinprognosisforbreastcancer AT denizyamac receptorstatusdifferencesinprognosisforbreastcancer AT ugurcoskun receptorstatusdifferencesinprognosisforbreastcancer |